As I mentioned, the process for new brand name drugs coming onto the market in the F1 category has not changed. Whether those drugs will be listed in F1 will depend upon the evaluation, as I mentioned before, by the Pharmaceutical Benefits Advisory Committee. They will make that decision. They make a decision based upon medical efficacy and cost-effectiveness. That will not change. The drugs will be accepted by the PBAC only if they are the most cost-effective drugs available.